This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Asia
October 21 - 23, 2024
Presented in Japan Standard Time

The Westin Miyako Kyoto
Delivered as a Hybrid Event

Satoshi Tamaki, PhD
CEO and CSO at MOLCURE Inc.
Speaker

Profile

Since 2015, Dr. Tamaki has served as the CSO at MOLCURE, where he has been instrumental in developing next-generation biopharmaceutical exploration technology. This technology integrates artificial intelligence (AI), evolutionary molecular engineering, and laboratory automation. In 2024, he was also appointed as the CEO of MOLCURE, where he continues to shape the company’s vision and growth strategy. Dr. Tamaki earned his Ph.D. in Media and Governance from Keio University.

Agenda Sessions

  • Integration of AI and Wet-Lab Discovery for the Generation of Diverse Antibodies

    14:30